Here are five things to note:
1. The case study considered ambulation ability impact and quality of life measurements.
2. After six months of use, the patient could walk independently, and experienced improvements in mobility, falling risks, motor skills and bladder control.
3. ReWalk is CE marked and FDA cleared.
4. The study called for additional studies with more patients.
5. “The ReWalk system on the one hand creates an additional possibility of mobility for the patient, but is moreover also an excellent therapy and training tool for people with complete or incomplete paraplegia,” said Professor Dr. med. Karsten Krakow.
More articles on devices:
5 of Medtech’s biggest deals of 2015
Thuasne Group acquires Quinn Medical — 5 takeaways
7 new device launches & releases — January 26, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
